+1 (424) 212-4087

Recurrent Implantation Failure in Torrance: A Complete Guide to Causes, Evaluation, and What Evidence Actually Supports

Few experiences in fertility treatment are as discouraging as a transfer that was supposed to work and did not. After one failed cycle, most patients are told that implantation is a matter of chance and that the next attempt may be the one. After two, three, or more — especially when the embryos were graded highly or tested and found to be chromosomally normal — that reassurance stops being enough. Patients start asking a harder question: if the embryo was good and the lining looked right, why did it not implant?

This guide is written for patients in Torrance and the South Bay who are confronting that question. It explains what recurrent implantation failure (RIF) is and — just as importantly — what it is not; how the leading reproductive medicine society now defines it; which causes are supported by evidence; which evaluations are considered reasonable; and which popular tests and add-on treatments current guidelines advise against. Throughout, one principle holds: every statistic and range described here is a population-level figure drawn from published research and professional guidance. It is not a prediction about your body, your cycle, or your outcome, and it is not a clinic-specific result, guarantee, or promise. Your own prognosis comes from your own history, tests, and embryos, discussed with your physician.

1. What Recurrent Implantation Failure Is — and What It Is Not

Implantation is the process by which a blastocyst attaches to and then penetrates the endometrium, the uterine lining. Biologically, it begins roughly five to seven days after fertilization. Clinically, it is first detected through a pregnancy hormone (hCG) in blood or urine, and later confirmed when an intrauterine gestational sac can be seen on ultrasound. Recurrent implantation failure refers to a pattern in which embryos transferred in an IVF cycle repeatedly do not establish that early pregnancy signal.

The word “recurrent” carries real weight, and this is where precision matters. There is no single, universally agreed-upon definition of RIF, and that is not an oversight — it reflects genuine biological complexity. Some definitions focus only on the number of failed transfers. Newer ones try to account for the patient’s age, embryo quality, and whether embryos were genetically tested. The American Society for Reproductive Medicine (ASRM), in a 2026 committee opinion, argued that any sensible definition must be individualized rather than a fixed count. We explain that reasoning in the next section.

It is also essential to separate RIF from a distinct but related problem: recurrent pregnancy loss (RPL). In RPL, a pregnancy is established — a pregnancy test turns positive, and often a gestational sac is seen — but is then lost, repeatedly. In RIF, the early pregnancy signal itself never reliably appears after transfer. The causes, evaluation, and treatment conversations differ, even though the emotional experience can feel similar. Mixing the two leads to the wrong tests and the wrong reassurance. If you are not certain which pattern applies to you, that distinction is the first thing to clarify with your team.

2. How ASRM Defines RIF — and Why It Is Not a Simple Number

The 2026 ASRM committee opinion on recurrent implantation failure recommends defining RIF as the failed implantation of the estimated number of good-quality blastocysts needed to achieve a 95% cumulative chance of a positive pregnancy test. In plainer terms: if, based on age and embryo status, enough good embryos were transferred that the chance of at least one implanting should have been about 95%, and still none did, that is the pattern worth investigating as RIF.

Why frame it this way instead of saying “three failed transfers”? Because the same number of failures means very different things for different people. For a patient in her late twenties transferring untested embryos, three failures might still fall within ordinary chance. For a patient in her early forties, or one transferring embryos known to be chromosomally normal, three failures is a much stronger signal. The literature suggests that for transfers of euploid (chromosomally normal) embryos, this threshold may be reached after roughly three to six failed transfers; for untested embryos, the number depends heavily on age. ASRM also notes that some researchers question whether RIF is a distinct clinical entity at all, arguing that with enough successive transfers of normal embryos, nearly everyone eventually implants — a statistical rather than a biological explanation.

This is why a careful clinic will not diagnose RIF from a count alone. A full review of the underlying evaluation, the embryos, and the cycle details comes first. For broader background on where implantation sits in the treatment sequence, see Understanding the IVF Journey and our guide to fresh versus frozen embryo transfer.

3. The Leading Cause: Embryo Chromosomes and Age

If there is one finding that has reshaped how specialists think about RIF, it is this: ASRM states that age-related aneuploidy — an abnormal number of chromosomes in the embryo — is generally believed to be the principal cause of implantation failure. Aneuploid blastocysts have very limited potential to implant and sustain a pregnancy or result in a live birth. An embryo can look excellent under the microscope and still carry a chromosomal error that makes implantation impossible.

The frequency of aneuploidy rises steeply with age. Reported figures are approximately 30% in women in their late twenties and early thirties, rising to roughly 50% at age 38 and around 90% by age 45. These are population-level estimates from published research, not odds for any individual. They explain why age is such a powerful factor in implantation and why two patients with the same number of failed transfers may need very different conversations. They also explain why doctors are cautious about promising that a “good-quality” embryo will implant: morphology and chromosomal normalcy are not the same thing.

This connects directly to ovarian reserve. A patient with low AMH or diminished reserve, or with premature ovarian insufficiency, may produce fewer eggs per cycle, which means fewer embryos to work with and fewer chances for a normal one to appear — a distinct issue from why any single embryo failed to implant. Understanding the difference helps patients avoid blaming themselves or their clinic for what is often a biological constraint.

4. The Uterine Cavity: Structure, Polyps, Fibroids, and Scarring

The second major area of investigation is the uterine cavity — the space where the embryo must attach. Before any transfer, evaluating the cavity to rule out structural problems is a well-established step. These include a septate uterus (a partition dividing the cavity), endometrial polyps, fibroids that bulge into the cavity, and intrauterine adhesions (scar tissue). Any of these can interfere with implantation, and some are correctable.

ASRM notes that for patients diagnosed with RIF, it is reasonable to repeat the uterine and tubal assessment, using methods such as sonohysterography (SHG), hysteroscopy, hysterosalpingography (HSG), or three-dimensional ultrasound. Sonohysterography tends to identify more endometrial abnormalities than HSG alone, and three-dimensional ultrasound is another reliable option. Hysteroscopy has the added advantage that a surgeon can treat certain problems — such as removing submucosal fibroids or polyps — during the same procedure. However, the committee also points to a large randomized trial in which hysteroscopy did not improve outcomes for RIF patients who had normal-appearing linings on ultrasound, so this is a decision to individualize rather than an automatic step. Fibroids that do not distort the cavity remain a separate question, with insufficient evidence to make a firm treatment recommendation.

The fallopian tubes deserve attention too. A hydrosalpinx — a blocked, fluid-filled tube — can affect the uterine environment, which is why tubal factor infertility is part of the broader workup. The goal of this entire review is straightforward: find and correct anything that can genuinely be corrected, then stop looking.

5. Chronic Endometritis and Endometriosis

Beyond gross structural problems, the microscopic state of the endometrium matters. Chronic endometritis is a persistent, often quiet inflammation of the uterine lining, usually caused by infection. ASRM reports some observational evidence supporting testing for it and treating it with antibiotics in patients with RIF. Diagnosis can involve an endometrial biopsy looking for specific immune cells, though the committee notes there is no agreed-upon threshold for how many of these cells constitute disease — a limitation that makes interpretation less certain than patients often hope.

Endometriosis and adenomyosis are also more prevalent in women with RIF, and higher-quality studies are needed to guide how best to diagnose and treat them. ASRM notes limited evidence supporting the use of GnRH agonist medication or surgery before transfer in women with adenomyosis, and suggests that pre-cycle treatment with a GnRH agonist and an aromatase inhibitor may be considered for patients with known or suspected endometriosis or adenomyosis together with RIF. Patients with endometriosis will recognize how often this condition sits behind other fertility diagnoses. These are nuanced, individualized decisions — not default add-ons for everyone.

6. Parental Chromosomes and Inherited Factors

In a minority of couples, a structural chromosomal rearrangement carried by one partner — a translocation or inversion, for example — can be the underlying reason embryos repeatedly fail. ASRM states that parental karyotyping may be considered to investigate structural rearrangements. If a parental chromosomal abnormality is found, genetic counseling is recommended, and a specialized form of embryo testing known as PGT-SR may be offered. This is different from routine aneuploidy screening and targets the specific inherited rearrangement.

This is also where the conversation broadens beyond IVF mechanics. Couples with a family history of genetic conditions, or repeated losses for unexplained reasons, may benefit from the kind of counseling covered in our guides to preimplantation genetic testing and to male factor and ICSI, since how an embryo was created can affect both its chromosomal status and how many are available to transfer.

7. PGT-A in RIF: Useful Information, Not a Guarantee

Because aneuploidy is so often the culprit, it is natural to ask whether testing embryos for chromosomal normalcy — preimplantation genetic testing for aneuploidy, or PGT-A — solves the problem. The answer from ASRM is careful and honest. In a shared decision-making model, PGT-A may be offered to patients who have experienced RIF with untested embryos, as a way to investigate whether embryo ploidy is contributing to the failures. Knowing that an embryo is euploid can be genuinely informative.

But the committee is explicit that this is not the same as proving a treatment benefit: there is no evidence that PGT-A increases the chance of live birth specifically for patients with RIF, and overall PGT-A has not been shown to improve live birth rates in infertile patients generally. ASRM also notes that no study has specifically demonstrated improved implantation or live birth in an RIF population after PGT-A. This distinction — information versus a proven fix — matters. Patients who want the deepest possible understanding of their embryos may reasonably choose testing; patients should not be told it will overcome repeated failure. Our dedicated PGT guide explains what the test can and cannot show.

8. Endometrial Receptivity Testing (ERA): What the Evidence Shows

If the embryo is normal and the cavity looks fine, the next suspicion often falls on timing — the idea that the lining was not “receptive” on the day of transfer. Endometrial receptivity testing, commonly called ERA, examines the gene-expression pattern of the lining to estimate whether the standard transfer window is right for that patient. The theory is appealing, and early studies suggested improved outcomes.

More recent evidence has been far less encouraging. ASRM describes the evidence as conflicting, noting that a large randomized trial found that using ERA to guide the timing of a frozen transfer of a euploid embryo, compared with standard timing, did not significantly improve live birth rates. A secondary analysis of that study reported a diagnostic accuracy measure (an area under the curve of 0.52) indicating poor ability to predict implantation failure. The committee’s conclusion is direct: there is insufficient evidence to support the routine use of ERA testing in patients with RIF. If a clinic offers it, that is a conversation about uncertain benefit and added cost, not an established standard of care.

9. Add-Ons That Current Guidelines Do Not Routinely Recommend

RIF is a fertile ground for well-intentioned but unproven interventions. Because the situation is distressing, it is understandable to want to do something more. ASRM reviewed a number of popular additions and found insufficient evidence to recommend them routinely. Knowing this list in advance can help patients spend their time and money deliberately rather than out of fear.

  • Endometrial scratching (endometrial injury). Despite earlier enthusiasm, ASRM concludes that evidence suggests it is not effective and does not recommend it for RIF.
  • Immunologic therapies. Treatments such as intravenous immunoglobulin, granulocyte colony-stimulating factor, intravenous fat emulsion, and similar agents have been studied, but the committee finds insufficient evidence to support routine use in RIF.
  • Blood thinners and clotting tests. ASRM reports no clear association between antiphospholipid antibody syndrome and RIF, and insufficient evidence for routine anticoagulation or routine clotting-panel testing in this population.
  • BCL-6 testing. Because evidence on its validity and on the effectiveness of any resulting treatment conflicts, routine BCL-6 testing is not recommended.
  • Sperm DNA fragmentation testing. This may be considered in the evaluation of recurrent pregnancy loss, but ASRM finds insufficient evidence to recommend it routinely in RIF.

None of this means these topics are irrelevant to every patient; individual findings can still justify an individualized discussion. It means that as a general rule, a large and growing body of professional guidance does not support adding them automatically after failed transfers. Patients with male-factor concerns, including a zero sperm count, should have that evaluated on its own merits rather than as a reflexive RIF add-on.

10. Progesterone Support and Transfer Timing

Progesterone prepares and maintains the uterine lining, so it is central to any pregnancy — and especially to programmed frozen embryo transfer cycles, in which the body is not making its own progesterone. Patients understandably wonder whether a different progesterone dose or route could explain a failed transfer. On this point, ASRM states that there are insufficient data to recommend a particular progesterone supplementation protocol specifically for patients with RIF. In other words, there is no proven “RIF protocol” for luteal support; standard embryo-transfer guidance applies, and the details belong to the treating physician.

This is an area where the same advice applies to the general IVF population: follow the medication plan you were given rather than adjusting or adding hormones on your own. Our guide to endometrial preparation describes how lining development is monitored and why timing is treated so carefully.

11. Lifestyle, Weight, and What You Can Actually Control

It is human to search for something in daily life that could have made the difference. ASRM encourages patients to achieve a healthy weight before pregnancy attempts, while noting that time spent losing weight must be weighed against the effect of advancing age on outcomes. The committee also states that while lifestyle interventions have not been demonstrated to improve outcomes specifically in RIF, a healthy lifestyle and cessation of smoking, tobacco, and illicit drug use are recommended for general health for both partners and before pregnancy.

This is honest framing: these habits are worth adopting for health, but they are not a demonstrated cure for implantation failure, and they should never become a source of blame. Patients who want a grounded, evidence-based discussion of diet, supplements, sleep, and daily habits can turn to our nutrition and lifestyle guide. No patient should be told that a failed transfer means they did not rest, eat, or think correctly.

12. The Emotional Weight of Repeated Failure

The clinical discussion about chromosomes and receptivity is only half the experience. Repeated failed transfers bring grief, anxiety, and often a sense of isolation, particularly when friends or family members conceive without difficulty. Patients may feel pressure to keep trying immediately, or may quietly wonder whether they should stop. Both reactions are valid, and neither is a sign of weakness.

It is reasonable — and often helpful — to build support into the plan rather than treating it as separate from treatment. Our guide to fertility stress and emotional support covers coping strategies, counseling, and communication with a partner. Patients who are navigating a later or second family may also recognize the themes in our secondary infertility guide. A treatment plan that ignores the person undergoing it is not a complete plan.

13. When No Cause Is Found: The Case for Moving Forward

Perhaps the most important message in the ASRM committee opinion is its conclusion. When a patient with RIF has had a comprehensive review of medical and reproductive history, imaging, and IVF cycle details, and no clear, correctable cause is identified, the committee advises that extensive further testing is unnecessary. It is reasonable to proceed with additional embryo transfers, because many patients ultimately will achieve pregnancy. This is not a statement of false optimism; it reflects the reality that implantation is partly probabilistic, and that a defined cause is not found in every case.

For patients, this can be a turning point. It means that “we do not have a single explanation” is not the same as “there is nothing more we can do.” It also means being wary of any recommendation to keep adding tests and treatments without a clear rationale. A good conversation names what has been checked, what was found, what could still be changed, and what the plan is if the next transfer also fails. Whether the path ahead involves another IVF cycle, a different approach such as IUI versus IVF, or preserving options through fertility preservation, the decision should be made with full information rather than in a rush to fix an unexplained failure.

14. Questions Worth Asking Your Team

  1. Does my history actually meet a definition of recurrent implantation failure, given my age and whether my embryos were tested?
  2. How many good-quality embryos were transferred, and were any of them known to be euploid?
  3. Was my uterine cavity evaluated, and with which method — and is there any reason to repeat it?
  4. Is there evidence of a correctable factor such as a polyp, fibroid, scarring, hydrosalpinx, or chronic endometritis?
  5. Which additional tests do you recommend for me specifically, and what would we do differently based on each result?
  6. Which add-on therapies are you suggesting, and what is the evidence that they improve live birth for someone in my situation?
  7. If we find no correctable cause, what is the plan for the next transfer and the one after that?

A clinic that can answer these questions plainly, using your own numbers and citing the reasoning behind each recommendation, is doing its job. Vague answers, guaranteed outcomes, or pressure to buy a long menu of unproven add-ons deserve a second opinion.

15. Frequently Asked Questions

How many failed transfers count as recurrent implantation failure?

There is no single universal number. ASRM defines RIF as failed implantation after transferring the estimated number of good-quality blastocysts needed for a 95% cumulative chance of a positive pregnancy test. For transfers of chromosomally normal (euploid) embryos, the literature suggests this may be roughly three to six failed transfers; for untested embryos it depends heavily on age.

Is RIF the same as recurrent miscarriage?

No. In recurrent implantation failure, an early pregnancy signal does not reliably appear after transfer. In recurrent pregnancy loss, a pregnancy is established and then lost repeatedly. They have different causes and different evaluations, though both are emotionally difficult.

What is the most common reason an embryo does not implant?

ASRM identifies age-related chromosomal abnormality (aneuploidy) in the embryo as the principal cause of implantation failure. Aneuploidy becomes more common with age, which is why age and embryo status shape the entire conversation.

Should I do ERA testing after failed transfers?

ASRM concludes there is insufficient evidence to support routine ERA testing in patients with RIF. A large randomized trial found that using ERA to time a frozen transfer of a euploid embryo did not significantly improve live birth rates compared with standard timing.

Are immune treatments, blood thinners, or endometrial scratching recommended?

Generally no. ASRM finds insufficient evidence to support routine immunologic therapies or anticoagulation in RIF, reports no clear link between antiphospholipid syndrome and RIF, and states that endometrial scratching is not effective and is not recommended. Individual circumstances can still warrant a discussion with your physician.

Does PGT-A improve the chance of a baby after RIF?

PGT-A can provide useful information about whether embryo chromosomes are contributing to the failures, and may be considered in shared decision-making after transfers of untested embryos. However, ASRM states there is no evidence that PGT-A increases the chance of live birth specifically in patients with RIF.

If no cause is found, should we keep trying?

Often yes. ASRM advises that after a thorough review finds no clear, correctable cause, extensive additional testing is unnecessary, and it is reasonable to proceed with further transfers — many patients ultimately achieve pregnancy. The decision is yours to make with your medical team.

For authoritative background on recurrent implantation failure and IVF, the American Society for Reproductive Medicine publishes a patient fact sheet library through ASRM’s ReproductiveFacts.org and practice guidance for clinicians on ASRM’s practice committee documents page. Plain-language information on infertility is also available from NICHD and MedlinePlus.

Medical and informational disclaimer: This article is general educational information, not medical advice, and it is not a substitute for evaluation by a qualified reproductive endocrinology specialist. Any statistics, percentages, or ranges mentioned are population-level figures from published research, guidelines, and authoritative sources (such as ASRM, NICHD, MedlinePlus, and professional society guidance); they are typical ranges for groups, not predictions about any individual, and they are not clinic-specific results, guarantees, or quotes. Whether you have recurrent implantation failure, which evaluations or treatments are appropriate, all medications, and all costs should be discussed directly with your medical team in a written, individualized assessment before any decision.

Incinta Fertility Center — Fertility Clinic Torrance & South Bay, California

By the Incinta Editorial Team · Medically reviewed by the Incinta Review Team

Call us: +1 (424) 212-4087